Company: OSRH
Filing Date: 2025-01-31
Form Type: 424B3
Source: 0001213900-25-008874
Chunk: 543

Company: OSR Holdings, Inc.
Filing Date: 2025-01-31
Form: 424B3
Chunk 543
---
 flow information Cash paid during the periods for:   |     |                           |             |   |     |      |             |   |
| Income taxes                                                                         |     | $                         |     461,957 |   |     | $    |           — |   |
| Supplemental disclosure of noncash investing and financing activities                |     |                           |             |   |     |      |             |   |
| Deferred underwriters’ discount payable charged to additional paid-in capital        |     | $                         |           — |   |     | $    |   2,070,000 |   |

The accompanying notes are an integral part of the unaudited condensed financial statements.

F-5 BELLEVUE LIFE SCIENCES ACQUISITION CORP. NOTES TO CONDENSED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (UNAUDITED) NOTE 1 — DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION Bellevue Life Sciences Acquisition Corp. (the “Company”) was incorporated in Delaware on February 25, 2020. The Company was incorporated for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities (the “Business Combination”). The Company is an emerging growth company and, as such, the Company is subject to all of the risks associated with emerging growth companies. As of September 30, 2024, the Company had not commenced any operations. All activity since inception relates to the Company’s formation and the initial public offering (“Initial Public Offering”) which is described below. The Company will not generate any operating revenues until after the completion of an initial Business Combination, at the earliest. The Company will generate non -operatingincome in the form of interest income from the proceeds derived from the Initial Public Offering. The registration statement for the Company’s Initial Public Offering (the “Registration Statement”) was declared effective on February 9, 2023. On February 14, 2023, the Company consummated the Initial Public Offering of 6,000,000 units (“Units” and, with respect to the common stock included in the Units being offered, the “Public Shares”), generating gross proceeds of $60,000,000, which is described in Note 3. On February 17, 2023, the underwriters exercised their over -allotmentoption in full. The closing of the issuance and